What the FDA labels say about taking them together
Fingolimod and teriflunomide
Fingolimod's FDA label of July 22, 2026 names teriflunomide in its drug interactions section; the teriflunomide label PlainMeds reads does not name fingolimod. The fingolimod label: “When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive …”
Check it at the source: the fingolimod FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation); the teriflunomide FDA label on DailyMed (effective February 20, 2026, Genzyme Corporation).
What does the fingolimod label say about teriflunomide?
Fingolimod label, drug interactionsWhen switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].
Source: FDA drug label (Tascenso Odt, NDA214962), Cycle Pharmaceuticals Ltd, effective January 20, 2026 (SPL set bf8e7f89-ea09-43c7-a7eb-e44724350721), via openFDA
Source: FDA drug label (Gilenya), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set cc9e1c8c-0e2b-44e2-878b-27057f786be9), via openFDA; the full label on DailyMed
What does the teriflunomide label say about fingolimod?
Teriflunomide's label (effective February 20, 2026) does not name fingolimod in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Aubagio), NDA202992 (Sanofi Aventis Us), as published by Genzyme Corporation, effective February 20, 2026 (SPL set 4650d12c-b9c8-4525-b07f-a2d773eca155), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fingolimod | Teriflunomide | |
|---|---|---|
| Labeled for | Multiple sclerosis | Multiple sclerosis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.58 per capsule 0.5 mg capsule | $0.233 per tablet 14 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once